Articles tagged "Induction therapy"

2022 American Transplant Congress
Long-Term Low-Dose Corticosteroid Therapy Can Suppress Calcineurin Inhibitor Induced Nephrotoxicity without Steroid-Related Complication in Living Kidney Transplant Recipient
H. Sasaki, H. Harada, D. Takamoto, Y. Takada, S. Harada, H. Tanaka
Sapporo City General Hospital, Sapporo, Japan
*Purpose: The induction of calcineurin inhibitors (CNI) greatly reduced the rate of allograft rejection, although their chronic use resulted in vascular inflammation in kidney transplant…
2022 American Transplant Congress
Extended Duration of Rabbit Antithymocyte Globulin (rATG) Induction in Kidney and Kidney/Pancreas Transplant Recipients
D. Majmundar, A. Di Carlo, A. Diamond
Temple University Hospital, Philadelphia, PA
*Purpose: Many transplant centers have endorsed an expanded duration of rabbit antithymocyte globulin (rATG) in the outpatient setting through peripheral administration to help minimize cost.…
2022 American Transplant Congress
Outcomes of Primary Kidney Transplant Recipients with Human Immunodeficiency Virus According to Induction Immunosuppression in the United States
K. Bhunia¹, K. Swanson¹, A. Bregman¹, R. El-Rifai¹, R. Spong¹, S. Jackson², S. Riad³
¹MEDICINE, University of Minnesota, Minneapolis, MN, ²Analytics, MHealth-Fairview, Minneapolis, MN, ³Medicine, University of Minnesota, Minneapolis, MN
*Purpose: Early reports of outcomes in recipients with HIV suggested lower kidney rejection rate in association with depletional induction. However, these reports did not assess…
2022 American Transplant Congress
Alemtuzumab and Basilximab Induction Therapy in Lung Transplantation
M. Furukawa, E. Chan, P. G. Sanchez
Cardiothoracic Surgery, UPMC, Pittsburgh, PA
*Purpose: Induction therapy is used in about more than 80% of lung transplant centers and is increasing globally. Currently, there are no standards or guideline…
2022 American Transplant Congress
Standard Induction with Basiliximab versus no Induction in Low Immunological Risk Kidney Transplant Recipients: Study Protocol for a Randomized Controlled Trial
A. Ajlan¹, H. Aleid¹, T. Ali¹, H. Joharji¹, Z. Alabdulkarim¹, T. Aburiash¹, K. Almeshari¹, A. Nazmi¹, Y. Shah¹, E. Devol¹, D. Alkortas¹, D. Broering¹, I. Alahmadi¹, A. Ullah¹, A. Alotaibi¹, A. Aljedai²
¹KFSHRC, RIYADH, Saudi Arabia, ²MOH, RIYADH, Saudi Arabia
*Purpose: To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC…
2022 American Transplant Congress
Reduction of Rabbit Anti-Thymocyte Globulin Dosing for Induction of Kidney Transplant During the COVID-19 Pandemic
C. Burrelli¹, S. Gundling¹, D. Ecabert¹, R. Powell¹, A. Padiyar¹, K. Andreoni¹, K. Chavin², A. Bixby¹
¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²University Hospitals Cleveland Medical Center / Case Western Reserve, Cleveland, OH
*Purpose: Rabbit anti-thymocyte globulin (rATG) is a polyclonal antibody utilized for induction immunosuppression in high immunologic risk kidney transplant recipients. However, the optimal total dose…
2022 American Transplant Congress
Tacrolimus After Rabbit Antithymocyte Globulin And Infliximab Induction Immunosuppression In Kidney Transplantation
O. Viklicky¹, G. Bold², O. Bestard³, P. Hruba¹, I. Zahradka¹, N. M. Otto², M. Stein², A. Sefrin², S. Christakoudi⁴, P. M. Reinke²
¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²Charité, Berlin, Germany, ³Vall d'Hebron, Barcelona, Spain, ⁴King's College, London, United Kingdom
*Purpose: Selective targeting of effector/memory T cells as induction immunosuppression has been discussed in kidney transplantation. Confidence-interval-estimation study may help to estimate range of the…
2022 American Transplant Congress
A Single Center Experience of Simultaneous Heart-Kidney Transplantation
A. Samra¹, A. Mattoo²
¹Nephrology, New York University Langone Transplant Institute, New York, NY, ²New York University Langone Transplant Institute, New York, NY
*Purpose: Currently there are no UNOS guidelines regarding the selection criteria required for simultaneous heart-kidney transplant recipients (SHKT). As of 2018 our center has begun…
2022 American Transplant Congress
Costs Associated with Induction Therapy for Pediatric Kidney Transplantation
N. M. Rodig¹, H. Pizzo², D. Levy Erez³, T. Richardson⁴, M. Somers¹
¹Boston Children's Hospital, Boston, MA, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Children’s Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital Association, Lenexa, KS
*Purpose: Choice of induction agent for pediatric kidney transplantation (KTx) is often based upon patient characteristics and center practice; costs associated with this choice have…
2022 American Transplant Congress
Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients
K. Progar¹, K. Kurwicki², N. Nesselhauf³, J. Hagopian⁴, S. January⁵, H. Wijeweera⁶, M. McCloskey⁷, M. Merzkani⁸, R. Delos Santos⁹
¹Transplant, Barnes-Jewish Hospital, St. Louis, MO, ²SSM Health Saint Louis University Hospital, Saint Louis, MO, ³Barnes-Jewish Hospital, Edwardsville, IL, ⁴Pharmacy, University of Michigan, Ann Arbor, MI, ⁵Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ⁶Washington University, Saint Louis, MO, ⁷Barnes-Jewish Hospital, St. Louis, MO, ⁸Washington University, St Louis, MO, ⁹Transplant, Washington University, St. Louis, MO
*Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…